Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

NCT: NCT04595474 · ACTIVE_NOT_RECRUITING

NCT IDNCT04595474
StatusACTIVE_NOT_RECRUITING
Start Date2021-01-14
Completion2026-12-30

Brief Summary

The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of identifying high-risk patients with advanced fibrosis who should be prioritized for specialty referral

Frequently Asked Questions

What is Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes?

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes is a clinical trial registered under NCT04595474. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04595474?

The current status of NCT04595474 (Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes) is: ACTIVE_NOT_RECRUITING.

When did Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes start?

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes started on 2021-01-14.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑